Evaluation of toxicity and effectiveness of the anti-malaria preparation mefloquine with respect to SARS-CoV-2 in experiments on animals

封面

如何引用文章

全文:

详细

The aim of the study was to clarify the toxicity of mefloquine and to evaluate the effectiveness of its use for Syrian hamsters infected with sARS-Cov-2.

Material and methods. The experiments were performed on 96 Syrian hamsters. The toxicity of mefloquine was determined with a single administration, as well as with a course of administration at doses comparable to therapeutic for humans. To study the effectiveness of the drug against SARS-CoV-2 infection, a comprehensive indicator of the state of lung tissue and a comparison of the dynamics of viral load in the lungs were used.

Results. The LD50 of mefloquine with a single oral administration is 817 mg/kg, the maximum tolerated dose is 600 mg/kg. When administered for 7 days at a cumulative dose of 900 mg/kg, no death was observed. Administration of mefloquine to animals infected with SARS-CoV-2 was accompanied by a decrease in the severity of lung damage and a faster decrease of viral load in the lung tissue.

作者简介

K. Filin

Federal State Unitary Enterprise Research & Production Center “Pharmaceutical Protection” of the Federal Medical Biological Agency

Email: info@atompharm.ru

Konstantin N. Filin.

141402, Khimki, Moscow region.

俄罗斯联邦

V. Bykov

Federal State Unitary Enterprise Research & Production Center “Pharmaceutical Protection” of the Federal Medical Biological Agency

编辑信件的主要联系方式.
Email: bykov_imm@mail.ru
ORCID iD: 0000-0001-5755-4045

Vladimir N. Bykov - Doctor of Medical Science, Professor, Deputy Director for Research and Development of the Federal State Unitary Enterprise Research & Production Center “Pharmaceutical Protection” of the Federal Medical Biological Agency.

141402, Khimki, Moscow region.

SPIN-код: 6021-1970

Author ID: 250265; ID: 7003916780

Researcher ID: R-8689-2016

俄罗斯联邦

V. Gladkikh

Federal State Unitary Enterprise Research & Production Center “Pharmaceutical Protection” of the Federal Medical Biological Agency

Email: Gladkich2007@rambler.ru

Vadim D. Gladkikh.

141402, Khimki, Moscow region.

SPIN-код: 9272-6130

Author ID: 601432

俄罗斯联邦

I. Lugovik

RMC “Home of pharmacy” JSC

Email: info@doclinika.ru

Il'ya A. Lugovik.

188663, Kuzmolovsky, Leningrad region.

俄罗斯联邦

A. Grebenyuk

Pavlov First Saint Petersburg State Medical University; Saint Petersburg State Chemical Pharmaceutical University

Email: grebenyuk_an@mail.ru
ORCID iD: 0000-0002-9381-194X

Aleksandr N. Grebenyuk.

197022, Saint Petersburg; 197376, Saint Petersburg.

Scopus Author ID: 7003916780

ResearcherID: R-8689-2016

俄罗斯联邦

参考

  1. Temporary guidelines. Prevention, diagnosis and treatment of the new coronavirus infection «COVID-19». Version 4. 27.03.2020. Moscow: Ministry of Health of the Russian Federation [ Vremenny'e metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoy infekcii «COVID-19». Versiya 4. 27.03.2020. Moscow: Ministerstvo zdravooxraneniya Rossijskoj Federacii, 2020. 2020. (in Russian)
  2. Sarma P., Kaur H., Kumar H., Mahendru D., Avti P., Bhattacharyya A., et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020; 92(7): 776-85.
  3. Tang W., Cao Z., Han M., Wang Z., Chen J., Sun W. [et al.]. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369: m1849.
  4. WHO Solidarity Trial Consortium, Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q., et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021; 384(6): 497-511.
  5. Biot C., Daher W., Chavain N., Fandeur T., Khalife J., Dive D., De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006; 49(9): 2845-9.
  6. Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H. [et al.]. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6: 16.
  7. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. [et al.]. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2. Clin Infect Dis. 2020; 71(15): 732-9.
  8. Axfors C., Schmitt A.M., Janiaud P., Van't Hooft J., Abd-Elsalam S., Abdo E.F., et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1): 2349.
  9. Li R., Yin K., Zhang K., Wang Y.Y., Wu Q.P., Tang S.B., Cheng J.D. Application Prospects of Virtual Autopsy in Forensic Pathological Investigations on COVID-19. Fa Yi Xue Za Zhi. 2020; 36(2): 149-56.
  10. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection «COVID-19» Version 5. 08.04.2020. Moscow: Ministry of Health of the Russian Federation [ Vremenny'e metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii «COVID-19» Versiya 5. 08.04.2020. Moscow: Ministerstvo Ministry of Health of the Russian Federation, 2020. (in Russian)
  11. Sun W., He S., Martfriez-Romero C., Kouznetsova J., Tawa G., Xu M., et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 2017; 137: 165-72.
  12. Balasubramanian A., Teramoto T., Kulkarni A.A., Bhattacharjee A.K., Padmanabhan R. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Res. 2017; 137: 141-50.
  13. Fan H.H., Wang L.Q., Liu W.L., An X.P., Liu Z.D., He X.Q., et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl). 2020; 133(9): 1051-6.
  14. Filin K.N., Berzin I.A., Bykov V.N., Gladkikh V.D., Loginova S.Ya., Savenko S.V., Shchukina V.N. Experimental evaluation of the activity of the drug mefloquine against the SARS-Cov-2 coronavirus. Medicina ekstremal'nyh situaciy (Medicine of extreme situations). 2020; 3: 13-18. (in Russian)
  15. Sweeney T.R. The present status of malaria chemotherapy: Mefloquine, a novel antimalarial. Medicinal Research Reviews. 1981; 1(3): 281-301.
  16. Sweeney T.R. Drugs with Quinine-like Action. In: Peters W., Richards W.H.G. ed. Anti-malarial Drug II: Current Antimalarial and New Drug Developments: Springer-Verlag Berlin Heidelberg; 1984. Chapter 9; p. 267-324.
  17. Korte D.W. Jr., Heiffer M.H., Hacker M.P., Kintner L.D., Hong C.B., Lee C.C. Subchronic toxicity of the antimalarial drug, mefloquine hydrochloride (WR-142,490), in monkeys and dogs. Fed Proc Fed Am Soc Exp Bioi. 1979; 38: 680.
  18. Karbwang J., Na-Bangchang K. Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. Fundam Clin Pharmacol. 1994; 8(6): 491-502.
  19. Guidelines for conducting preclinical studies of medicines. Moscow: FSBI "NCESMP" of the Ministry of Health and Social Development of Russia; 2012.
  20. Desjardins R.E., Pamplin C.L. 3rd, von Bredow J., Barry K.G., Canfield C.J. Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther. 1979; 26(3): 372-9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Filin K.N., Bykov V.N., Gladkikh V.D., Lugovik I.A., Grebenyuk A.N., 2021


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.